Novo Nordisk Stock Eyes Worst Day Ever on Outlook Cut

Novo Nordisk (NVO) shares plummeted 21% to a nearly three-year low after the company unexpectedly slashed its full-year guidance, citing a lower sales outlook for several drugs. This significant revision, potentially marking the stock's worst daily drop on record and contributing to a 37.3% year-to-date decline, has spurred heavy options trading with notable activity in the September 45 puts. Concurrently, Maziar Mike Doustdar was named the new CEO.

Analysis

Novo Nordisk (NVO) experienced a historic single-day stock decline, plunging 21% to a near three-year low of $54.27, following an unexpected and significant downward revision of its full-year guidance. The cut, attributed to a weaker sales outlook for several drugs, exacerbated the stock's year-to-date loss, which now stands at 37.3%. Compounding this operational turmoil is a leadership transition, with the company naming Maziar Mike Doustdar as its new CEO. This negative news sharply reverses recent market sentiment, which saw call traders build bullish positions, evidenced by a 50-day call/put ratio of 2.87 that was at a one-year high. Post-announcement options volume has doubled its typical daily average, with notable activity in the September 45 puts. The selling of these puts suggests some market participants may view $45 as a potential floor or an attractive entry point. The stock's high Schaeffer's Volatility Scorecard of 79 further indicates a historical tendency for price moves to exceed volatility expectations, signaling the potential for continued sharp movements.

Key Decisions for Investors

• Given the severe guidance cut and concurrent CEO change, investors should reassess their fundamental thesis on NVO, as the magnitude of the sales outlook revision signals significant operational headwinds.
• Traders should monitor the options market, particularly the dynamic around the September 45 strike, as the selling of puts may indicate where some market participants believe a new support level could form.
• With the stock marking its worst daily drop on record and exhibiting a high historical tendency to outperform volatility expectations (SVS of 79), any new or existing positions should account for heightened price risk, making defined-risk strategies potentially more attractive.